Rigel Pharmaceuticals, Inc.
RIGL
Rank in Stocks
#9811
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides... Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Share Price
$42.05
Last synced: 2026-11-09
Market Cap
$785.49M
Change (1 day)
6.05%
Change (1 year)
10.80%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Rigel Pharmaceuticals, Inc. (RIGL)
Category
Healthcare
EPS for Rigel Pharmaceuticals, Inc. (RIGL)
EPS as of September 2026 TTM: $16.82
According to Rigel Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $16.82. At the end of 2025 the company had an EPS of $20.40, an increase over its 2024 EPS of $0.99.
EPS history for Rigel Pharmaceuticals, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $16.82 | -17.55% |
| 2025 | $20.40 | 1,960.61% |
| 2024 | $0.99 | -168.75% |
| 2023 | $-1.44 | -57.65% |
| 2022 | $-3.40 | 209.09% |
| 2021 | $-1.10 | -38.89% |
| 2020 | $-1.80 | -55.00% |
| 2019 | $-4.00 | -9.09% |
| 2018 | $-4.40 | -28.69% |
| 2017 | $-6.17 | -15.83% |
| 2016 | $-7.33 | 25.95% |
| 2015 | $-5.82 | -43.88% |
| 2014 | $-10.37 | 1.67% |
| 2013 | $-10.20 | 66.12% |
| 2012 | $-6.14 | 67.30% |
| 2011 | $-3.67 | -326.54% |
| 2010 | $1.62 | -159.34% |
| 2009 | $-2.73 | -25.61% |
| 2008 | $-3.67 | 42.80% |
| 2007 | $-2.57 | 70.20% |
| 2006 | $-1.51 | -27.05% |
| 2005 | $-2.07 | -33.65% |
| 2004 | $-3.12 | -13.81% |
| 2003 | $-3.62 | -50.48% |
| 2002 | $-7.31 | 27.13% |
| 2001 | $-5.75 | -81.71% |
| 2000 | $-31.43 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -6.90% |
US
|
|
| $-7.07 | -142.03% |
US
|
|
| $-5.29 | -131.45% |
AU
|
|
| $12.88 | -23.42% |
BE
|
|
| $21.56 | 28.18% |
NL
|
Questions about Rigel Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Rigel Pharmaceuticals, Inc.'s earnings per share (EPS)?
Rigel Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $16.82, as of Sep 2026.
What was Rigel Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Rigel Pharmaceuticals, Inc.'s earnings per share (EPS) was $20.40, 1,960.61% more than in 2024 ($0.99).
How has Rigel Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Rigel Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2025 ($20.40) and lowest in 2022 ($-3.40).
How does Rigel Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Rigel Pharmaceuticals, Inc.'s earnings per share (EPS) ($16.82) is higher than that of 4 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.